UC San Diego Moores Cancer Center New Member of National Comprehensive Cancer Network

 

March 20, 2013  |  

On March 19, the National Comprehensive Cancer Network® (NCCN®) announced the election of University of California, San Diego Moores Cancer Center as the first and only San Diego-based NCCN Member Institution dedicated to improving the quality, effectiveness, and efficiency of care provided to patients with cancer.

Moores Cancer Center 

UC San Diego Moores Cancer Center was elected as the first and only San Diego-based National Comprehensive Cancer Center Network Member Institution. 

“We are proud to join this prestigious alliance of the world’s leading cancer centers,” said Paul Viviano, CEO of UC San Diego Health System. “The physicians, scientists and clinicians of UC San Diego Moores Cancer Center and NCCN, share a vision of creating a healthier world, one life at a time, through new science, new medicine and new cures.”

As a NCCN Member Institution, UC San Diego Moores Cancer Center will be part of a national network that develops the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) used as the standard for clinical policy in oncology, incorporating expert medical judgment and recommendations of multidisciplinary panels from NCCN Member Institutions.

“The National Comprehensive Cancer Network and the UC San Diego Health System are bringing the most effective therapeutic and prevention strategies to cancer patients,” said Scott M. Lippman, MD, director of the Moores Cancer Center. “We look forward to working with fellow premier NCCN institutions to impact the outcomes of cancer care and to influence the direction of the cancer field.”

Joining 22 other institution members of NCCN, Moores Cancer Center was selected because of its role in transforming cancer care and providing exceptional care to cancer patients. Moores Cancer Center is the only National Cancer Institute (NCI)-designated Comprehensive Cancer Center in the San Diego region. Its multi-disciplinary team approach includes translating the basic scientific discoveries of its research faculty into new treatments for cancer patients in the clinic.

“We are extremely pleased that UC San Diego Moores Cancer Center has been elected to institutional membership in the NCCN,” said Robert Carlson, MD, CEO of the National Comprehensive Cancer Network. “Moores Cancer Center adds substantial strength and expertise to the excellence of cancer care, research, and education characteristic of the other world-class member institutions.”

About the National Comprehensive Cancer Network®
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 23 of the world’s leading cancer centers, is dedicated to improving the quality, effectiveness, and efficiency of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.

# # #

Media Contact: Yadira Galindo, 619-543-6163, ygalindo@ucsd.edu


Related Specialties

Cancer



Media Contact

Share This Article


Related News

2/15/2019
The Next Generation Precision Oncology Symposium, a novel meeting of industry and academic leaders in cancer science and medicine, will be held February 21, 2019 at UC San Diego Moores Cancer Center.
2/5/2019
To make it easier for patients to receive world-class cancer care, UC San Diego Health has added a new multidisciplinary cancer clinic in Hillcrest and expanded its infusion center for both oncology p ...
1/3/2019
UC San Diego researchers have found a stem cell enzyme copy edits more than 20 tumor types, providing new therapeutic target for preventing cancer cell resistance to chemotherapy and radiation.
12/7/2018
David Cheresh, Distinguished Professor at University of California San Diego School of Medicine, received $4.2 million National Cancer Institute Outstanding Investigator Award to continue his research ...



Follow Us